Tau protein abnormalities are key pathogenic features of Alzheimer disease and other neurodegenerative diseases. In 2015, new studies of the less common tauopathies, including progressive supranuclear palsy, chronic traumatic encephalopathy and frontotemporal lobar degeneration, have identified in vivo biomarkers and mechanisms that initiate tau pathology.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology
BioDrugs Open Access 16 April 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wang, Y. & Mandelkow, E. Tau in physiology and pathology. Nat. Rev. Neurosci. 17, 22–35 (2015).
Goedert, M. Alzheimer's and Parkinson's diseases: the prion concept in relation to assembled Aβ, tau, and α-synuclein. Science 349, 1255555 (2015).
Nag, S. et al. Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer disease. Ann. Neurol. 77, 942–952 (2015).
Schneider, J. A., Arvanitakis, Z., Leurgans, S. E. & Bennett, D. A. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann. Neurol. 66, 200–208 (2009).
Zhao, Y. et al. Appoptosin-mediated caspase cleavage of tau contributes to progressive supranuclear palsy pathogenesis. Neuron 87, 963–975 (2015).
Hoglinger, G. U. et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat. Genet. 43, 699–705 (2011).
Kondo, A. et al. Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature 523, 431–436 (2015).
Olivera, A. et al. Peripheral total tau in military personnel who sustain traumatic brain injuries during deployment. JAMA Neurol. 72, 1109–1116 (2015).
Rohrer, J. D. et al. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol. 14, 253–262 (2015).
Johnson, K. A. et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann. Neurol. http://dx.doi.org/10.1002/ana.24546 (2015).
Acknowledgements
J.C.R. and A.L.B. are supported by NIH (grants U54NS092089 and R01AG038791) and the Tau Consortium.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.L.B. has received research support from Avid, Biogen, Bristol Myers Squibb, C2N Diagnostics, Cortice Biosciences, Eli Lilly, Forum Pharmaceuticals, Genentech and TauRx. He has served as a consultant for Asceneuron, Ipierian, Ionis (formerly Isis) Pharmaceuticals, Janssen and Merck. He serves on a Data and Safety Monitoring Board for Neurogenetics Pharmaceuticals. He has stock and/or options in Alector and Delos. J.C.R. declares no competing interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Rojas, J., Boxer, A. Targeting tauopathies for therapeutic translation. Nat Rev Neurol 12, 74–76 (2016). https://doi.org/10.1038/nrneurol.2016.5
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2016.5
This article is cited by
-
Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies
Nature Reviews Neurology (2021)
-
Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology
BioDrugs (2020)
